FDA Approves SPEVIGO for Generalized Pustular Psoriasis Flares

TUESDAY, Sept. 6, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.
SPEVIGO is a novel, selective antibody infusion that blocks the activation of the interleukin-36 receptor, which is part of an immune system signaling pathway thought to be involved in the cause of GPP. The approval was based on a 12-week trial in which 53 patients with a GPP flare were treated with SPEVIGO or placebo. After one week, more patients treated with SPEVIGO showed no visible pustules than those treated with placebo (54 versus 6 percent).
The most common adverse reactions (≥5 percent) reported in patients taking SPEVIGO were asthenia and fatigue, nausea and vomiting, headache, pruritus and prurigo, infusion site hematoma and bruising, and urinary tract infection.
“GPP flares can greatly impact a patient’s life and lead to serious, life-threatening complications,” Mark Lebwohl, M.D., lead investigator for the trial, said in a statement. “The approval of SPEVIGO is a turning point for dermatologists and clinicians.”
Approval of SPEVIGO was granted to Boehringer Ingelheim.
Was this page helpful?
Related Posts
A Statin a Day Keeps Heart Trouble Away for Those With HIV
TUESDAY, July 25, 2023 (HealthDay News) – Heart disease is a high risk for...
Guard Dogs, Panic Buttons: Nurses Under Threat From Rising Violence
MONDAY, Nov. 1, 2021 (HealthDay News) -- Emergency room nurse Grace Politis was...
Convection-Enhanced Delivery of Topotecan Active in Glioblastoma
WEDNESDAY, Nov. 30, 2022 (HealthDay News) -- A subcutaneously implanted,...
New BA.2 COVID-19 Subvariant Taking Hold in United States
THURSDAY, May 5, 2022 (HealthDay News) -- Yet another subvariant of the omicron...